Genicular Nerve Block in Juvenile Idiopathic Arthritis

• Register: ClinicalTrials.gov
• Last refreshed on: 26 July 2021
• Main ID: NCT04687930
• Date of registration: 19/12/2020
• Prospective Registration: No
• Primary sponsor: Sohag University
• Public title: Genicular Nerve Block in Juvenile Idiopathic Arthritis
• Scientific title: Genicular Nerve Block in Juvenile Idiopathic Arthritis
• Date of first enrolment: December 1, 2020
• Target sample size: 104
• Recruitment status: Completed
• URL: https://clinicaltrials.gov/show/NCT04687930
• Study type: Interventional
• Study design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant).
• Phase: Phase 4

Countries of recruitment

Egypt

Key inclusion & exclusion criteria

Inclusion Criteria:

- juvenile idiopathic arthritis with persistent knee arthritis

- age below 16

Exclusion Criteria:

- severe knee osteoarthritis

- peripheral neuropathy,

- psoriatic arthritis,

- those under anticoagulant therapy, skin infection,

- prior knee injection in the last 3 months3

- those who have an allergy to Bupivacaine



Age minimum: N/A
Age maximum: 16 Years
Gender: All

Health Condition(s) or Problem(s) studied

no Other Cause for Chronic Kneearthritis

Persistent Knee Arthritis

no Intra-articular Injection in the Last 3 Months

Juvenile Idiopathic Arthritis

Intervention(s)

Drug: genicular nerve block

Drug: intra-articular steroid injection

Primary Outcome(s)

Change in semiquantitative score for swelling and tenderness over time [Time Frame: Baseline, 2 weeks and 12 weeks]

Change in visual analogue scale over time [Time Frame: Baseline, 2 weeks and 12 weeks]

Change in Lysholm score over time [Time Frame: Baseline, 2 weeks and 12 weeks]

Change in SOLAR score over time [Time Frame: Baseline, 2 weeks and 12 weeks]

Secondary ID(s)

8122020

Source(s) of Monetary Support

Please refer to primary and secondary sponsors